Gregory Mattingly
Biographic Data
| ID | 10445829 |
|---|---|
| NAME | Gregory Mattingly |
| GIVEN NAMES | Gregory |
| FAMILY NAME | Mattingly |
| SIGNATURE | MATTINGLY G |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice
This real-world study demonstrated improvements in functioning, depressive symptoms, and cognitive function in patients with MDD treated with vortioxetine in routine clinical practice in the cohort of patients enrolled in the United States. Outcomes were consistent with the efficacy and safety profile of vortioxetine in randomized controlled trials
The World Federation of ADHD International Consensus Statement
BACKGROUND: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. METHODS: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For net…
No prominent works on this page.
The World Federation of ADHD International Consensus Statement
BACKGROUND: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. METHODS: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For net…
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice
This real-world study demonstrated improvements in functioning, depressive symptoms, and cognitive function in patients with MDD treated with vortioxetine in routine clinical practice in the cohort of patients enrolled in the United States. Outcomes were consistent with the efficacy and safety profile of vortioxetine in randomized controlled trials
Medicine (2 works) · Psychiatry (2 works) · Psychology (2 works) · Adverse effect (1 work) · Attention Deficit Hyperactivity Disorder (1 work) · Cardiac Health and Mental Health (1 work) · Cognition (1 work) · Cohort (1 work) · Cohort study (1 work) · Consensus conference (1 work)